Boardroom Media (CFO News)
At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top China based CFO’ operating in the Biotechnology space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected]
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Billy Cho
Chief Financial Officer of Zai Lab
Billy Cho is our chief financial officer since March 2018. Prior to joining Zai Lab, Billy Cho was the Managing Director and Head of Asia Healthcare Investment Banking at Citigroup. Based in Hong Kong since 2011, Billy Cho was responsible for healthcare client coverage at Citigroup across the Asia Pacific region and led many important biopharma transactions in China including ZaiLab’s US IPO. Prior to this, he was based in New York in healthcare M&A investment banking and also spent time in corporate development for a pharmaceutical services company. Billy Cho started his career at Ernst & Young performing financial audits of US-based healthcare companies. Billy Cho earned his M.B.A. from the Wharton School of the University of Pennsylvania and M.A. in Accounting from University of Virginia.
Follow Billy Cho:
About Zai Lab: Zai Lab brings transformative medicines for cancer, autoimmune, and infectious diseases to patients in China and around the world.
Zidong Zhang
Chief Financial Officer of Shanghai Henlius Biotech
The company Chief Financial Officer, Dr. Zidong Zhang graduated from Fudan University for BS in chemistry, then obtained Ph.D. degree from Boston University in Biochemistry and MBA from Duke University the Fuqua School of Business. Dr. Zhang had worked as Equity Analyst for UBS in New York, covering US large Cap Pharmaceuticals and Specialty Pharmaceutical sector. He had a key focus in therapeutic areas as Oncology(especially for Immuno Oncology), autoimmune diseases, and other areas as Women’s health and CNS. He also developed a specialty and in-depth knowledge in generics market entry pathway and bio-similar entry/competition. Before UBS, healso worked for Bayer in the US as an internal consultant. He had multiple projects across US, Europe, and China, including strategic planning and market forecasts for US and China, merger and acquisition, organizational structure design and implementation, etc.
Follow Zidong Zhang:
About Novotech, Shanghai Henlius Biotech: Shanghai Henlius Biotech is joint venture company that provides clinical-stage biopharmaceutical services.
Richard Yeh
Chief Financial Officer of CStone Pharmaceuticals
Follow Richard Yeh:
About CStone Pharmaceuticals: CStone Pharmaceuticals is a bio-pharmaceutical company develops new treatments in a range of therapeutic areas.
Roy Xu
CFO of LYFE Capital
Roy Xu is a CFO at LYFE Capital and manages all financial operations at our Shanghai offices. Prior to joining LYFE Capital, he was VP at GP Capital where he focused on managing and execution of investment projects and led various due-diligence, compliance and risk-management projects onto completion. He has a plethora of knowledge and financial experience across various industry sectors from high tech (Healthcare/TMT) to goods-producing industries (agriculture/construction.) Additionally he has spent extensive time at Pricewaterhouse Coopers and Shenyin & Wanguo Investment Co. Although Roy started his career in Museum management, his attraction to finance was unequivocal which led him to becoming a top 3 performer at PwC as an Assurance Manager. He has enthusiastically taken on and successfully accomplished various China IPOs and engaged in various IFRS, US GAAP, HKFRS and SOX404 engagements. Roy received his Bachelors in Museology from Fudan University and was previously a CPA.
Follow Roy Xu:
About LYFE Capital: LYFE Capital is a life science investment firm.
Simon Xu
CFO of 3D Medicines
Follow Simon Xu:
About 3D Medicines: 3D Medicines mission is to improve people’s health through cancer personalized diagnostics and treatment.
Ming Yang
Chief Financial Officer of China Biologic Products
Yang has been our Chief Financial Officer since August 7, 2012, interim Chief Financial Officer since June 1, 2012 and our Vice President of Finance and Compliance and Treasurer since March 30, 2012. He is in charge of financial management, internal controls, legal and compliance matters as well as the implementation of corporate governance rules and policies. Mr. Yang has six years of financial management experience in corporations and 11 years audit experience in accounting firms. Mr. Yang has extensive experience in dealing with the PRC tax regulations, PRC GAAP, IFRS and internal control matters. He was an audit senior manager at KPMG, where he provided audit services for initial public offerings, right issues and merger and acquisition transactions. He also worked on the annual reports of various public companies listed in Hong Kong and mainland China. His audit clients ranged from state-owned enterprises and Chinese listed companies to multinational companies, including Angang Steel, Shenhua Energy, BOE Technology and BHP Billiton. Mr. Yang is a certified public accountant in China.
Follow Ming Yang:
About China Biologic Products: China Biologic Products is a company focused on the plasma-based biopharmaceutical industry.
Ling Lu
CFO of Laviana Pharma
Follow Ling Lu:
About Laviana Pharma: Laviana Pharmatech specializes in providing process and manufacture outsourcing services for the pharmaceutical industry.
Zhenshan Wu
CFO of Beijing Tiantan Biological Products
Zhenshan Wu is CFO at Beijing Tiantan Biological Products.
Follow Zhenshan Wu:
About Beijing Tiantan Biological Products: Beijing Tiantan Biological Products Corporation Limited specializes on the biopharmaceutical industry.
Delian Zhang
CFO of Laoken Medical Technology
Follow Delian Zhang:
About Laoken Medical Technology: Laoken Medical Technology is focused on the R&D and production of sterilization and disinfection products.
